Borkar Samiksha A, Yin Li, Venturi Guglielmo M, Shen Jerry, Chang Kai-Fen, Fischer Bernard M, Nepal Upasana, Raplee Isaac D, Sleasman John W, Goodenow Maureen M
Molecular HIV and Host Interactions Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive, Bethesda, MD 20894, USA.
Division of Allergy and Immunology, Department of Pediatrics, Duke University School of Medicine, Durham, NC 27710, USA.
Cells. 2025 Feb 15;14(4):285. doi: 10.3390/cells14040285.
Combination antiretroviral therapy (ART) suppresses detectible HIV-1 replication, but latent reservoirs and persistent immune activation contribute to residual viral-associated morbidities and potential viral reactivation. youth with HIV (YWH) virally suppressed on ART early in infection before CD4 T cell decline with fewer comorbidities compared to adults represent a critical population for identifying markers associated with viral control and predictors of viral breakthrough. This study employed a multi-omics approach to evaluate plasma biomarkers and cellular gene expression profiles in 52 participants, including 27 YWH on ART for 144 weeks and 25 youth with no infection (NI) (ages 18-24). Among the 27 YWH, 19 were virally suppressed (VS; <50 RNA copies/mL), while eight were non-suppressed (VNS; >50 RNA copies/mL). VS YWH displayed unique bioprofiles distinct from either VNS or NI. Early viral suppression mitigates inflammatory pathways and normalizes key biomarkers associated with HIV-related comorbidities. Genes upregulated in pathways linked to cellular homeostasis such as DNA repair, RNA processing, and transcription regulation may diminish viral breakthrough and maintain sustained HIV control on ART. Candidate markers and putative molecular mechanisms were identified, offering potential therapeutic targets to limit viral persistence, enhance HIV treatment strategies, and pave the way for improved clinical outcomes.
联合抗逆转录病毒疗法(ART)可抑制可检测到的HIV-1复制,但潜伏库和持续的免疫激活会导致残留的病毒相关发病率和潜在的病毒重新激活。与成年人相比,在感染早期CD4 T细胞下降之前就通过ART实现病毒抑制且合并症较少的感染HIV的青年(YWH)是识别与病毒控制相关的标志物和病毒突破预测指标的关键人群。本研究采用多组学方法评估了52名参与者的血浆生物标志物和细胞基因表达谱,其中包括27名接受ART治疗144周的YWH和25名未感染(NI)的青年(年龄在18至24岁之间)。在27名YWH中,19名实现了病毒抑制(VS;<50个RNA拷贝/毫升),而8名未实现病毒抑制(VNS;>50个RNA拷贝/毫升)。VS YWH表现出与VNS或NI不同的独特生物特征。早期病毒抑制可减轻炎症途径,并使与HIV相关合并症相关的关键生物标志物正常化。在与细胞稳态相关的途径(如DNA修复、RNA加工和转录调控)中上调的基因可能会减少病毒突破,并在ART治疗中维持持续的HIV控制。确定了候选标志物和推定的分子机制,为限制病毒持续存在、加强HIV治疗策略以及改善临床结果提供了潜在的治疗靶点。